title: SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia.
abstract: Selenium binding protein 1 (SELENBP1) messenger RNA (mRNA) has previously been shown to be upregulated in the brain and blood from subjects with schizophrenia. We aimed to validate these findings in a new cohort using real-time PCR in Brodmann's Area (BA) 9, and to determine the disease specificity of increased SELENBP1 expression by measuring SELENBP1 mRNA in subjects with major depressive disorder and bipolar disorder. We then extended the study to include other cortical regions such as BA8 and BA44. SELENBP1 mRNA was higher in BA9 (P = 0.001), BA8 (P = 0.003) and BA44 (P = 0.0007) from subjects with schizophrenia. Conversely, in affective disorders, there was no significant difference in SELENBP1 mRNA in BA9 (P = 0.67), suggesting that the upregulation may be diagnosis specific. Measurement of SELENBP1 protein levels showed that changes in mRNA did not translate to changes in protein. In addition, chronic treatment of rats with antipsychotics did not significantly affect the expression of Selenbp1 in the cortex (P = 0.24). Our data show that elevated SELENBP1 transcript expression is widespread throughout the prefrontal cortex in schizophrenia, and confirm that this change is a consistent feature of schizophrenia and not a simple drug effect.
authors.affiliation: 1] The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia [2] CRC for Mental Health, Carlton South, VIC, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Udawela
authors.affiliation: 1] The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia [2] CRC for Mental Health, Carlton South, VIC, Australia [3] Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia [4] North West Mental Health, Royal Melbourne Hospital, Parkville, VIC, Australia.
authors.forename: T T
authors.initials: TT
authors.lastname: Money
authors.affiliation: 1] The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia [2] CRC for Mental Health, Carlton South, VIC, Australia [3] Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Neo
authors.affiliation: The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia.
authors.forename: M S
authors.initials: MS
authors.lastname: Seo
authors.affiliation: 1] The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia [2] CRC for Mental Health, Carlton South, VIC, Australia [3] Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
authors.forename: E
authors.initials: E
authors.lastname: Scarr
authors.affiliation: 1] The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia [2] CRC for Mental Health, Carlton South, VIC, Australia [3] Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
authors.forename: B
authors.initials: B
authors.lastname: Dean
authors.affiliation: 1] The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, VIC, Australia [2] CRC for Mental Health, Carlton South, VIC, Australia [3] Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia [4] North West Mental Health, Royal Melbourne Hospital, Parkville, VIC, Australia.
authors.forename: I P
authors.initials: IP
authors.lastname: Everall
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001714:Bipolar Disorder / Q000378:metabolism; D016022:Case-Control Studies; D002746:Chlorpromazine / Q000494:pharmacology; D003865:Major Depressive Disorder / Q000378:metabolism; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017397:Prefrontal Cortex / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D012559:Schizophrenia / Q000378:metabolism*; D051137:Selenium-Binding Proteins / Q000032:analysis* / Q000096:biosynthesis; D013881:Thioridazine / Q000494:pharmacology
chemical_list: D014150:Antipsychotic Agents; C495175:SELENBP1 protein, human; D051137:Selenium-Binding Proteins; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine